RPID
Rapid Micro Biosystems, Inc.
Medical - Devices
Market Cap$114M
5Y Perf.-88.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RPID vs BIO
Revenue, margins, valuation, and 5-year total return — side by side.
BIO
Bio-Rad Laboratories, Inc.
Medical - Devices
Market Cap$6.95B
5Y Perf.-65.2%
RPID vs BIO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RPID | BIO |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $114M | $6.95B |
| Revenue (TTM) | $31M | $2.59B |
| Net Income (TTM) | $-44M | $169M |
| Gross Margin | 18.4% | 51.9% |
| Operating Margin | -148.8% | 9.2% |
| Forward P/E | — | 25.0x |
| Total Debt | $24M | $1.53B |
| Cash & Equiv. | $20M | $532M |
RPID vs BIO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RPID
BIO
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Rapid Micro Biosyst… (RPID) | 100 | 11.5 | -88.5% |
| Bio-Rad Laboratorie… (BIO) | 100 | 34.8 | -65.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RPID vs BIO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIO leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Rapid Micro Biosystems, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
RPID
Rapid Micro Biosystems, Inc.
The Growth Play
RPID is the clearest fit if your priority is growth exposure.
- Rev growth 19.7%, EPS growth 2.8%, 3Y rev CAGR 25.2%
- 19.7% revenue growth vs BIO's 0.7%
Best for: growth exposure
BIO
Bio-Rad Laboratories, Inc.
The Income Pick
BIO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.92
- 81.4% 10Y total return vs RPID's -88.0%
- Lower volatility, beta 0.92, Low D/E 20.5%, current ratio 5.62x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RPID | 19.7% revenue growth vs BIO's 0.7% |
| Quality / Margins | BIO | 6.5% margin vs RPID's -145.1% |
| Stability / Safety | BIO | Beta 0.92 vs RPID's 1.96, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIO | +10.7% vs RPID's +10.3% |
| Efficiency (ROA) | BIO | 2.2% ROA vs RPID's -51.6%, ROIC 2.6% vs -69.9% |
RPID vs BIO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
RPID vs BIO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBIOLAGGINGRPID
RPIDRapid Micro Biosystem…
0leads
BIOBio-Rad Laboratories,…
5leads
6 Total Categories
CATEGORYLEADERvs RPIDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BIO4/6
Valuation MetricsMultiples, price ratios, and targets
BIO2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BIO7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BIO4/6
Risk & VolatilityBeta, volatility, and downside exposure
BIO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BIO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIO is the larger business by revenue, generating $2.6B annually — 84.9x RPID's $31M. BIO is the more profitable business, keeping 6.5% of every revenue dollar as net income compared to RPID's -145.1%.
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| RevenueTrailing 12 months | $31M | $2.6B |
| EBITDAEarnings before interest/tax | -$42M | -$315M |
| Net IncomeAfter-tax profit | -$44M | $169M |
| Free Cash FlowCash after capex | -$39M | $357M |
| Gross MarginGross profit ÷ Revenue | +18.4% | +51.9% |
| Operating MarginEBIT ÷ Revenue | -148.8% | +9.2% |
| Net MarginNet income ÷ Revenue | -145.1% | +6.5% |
| FCF MarginFCF ÷ Revenue | -126.4% | +13.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.1% | +1.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -9.5% |
BIO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BIO leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| Market CapShares × price | $114M | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $118M | $7.9B |
| Trailing P/EPrice ÷ TTM EPS | -2.44x | 9.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.00x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 16.70x |
| Price / SalesMarket cap ÷ Revenue | 3.39x | 2.69x |
| Price / BookPrice ÷ Book value/share | 3.44x | 0.94x |
| Price / FCFMarket cap ÷ FCF | — | 18.55x |
BIO leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
BIO leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BIO delivers a 2.4% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-74 for RPID. BIO carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to RPID's 0.72x. On the Piotroski fundamental quality scale (0–9), BIO scores 5/9 vs RPID's 3/9, reflecting solid financial health.
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| ROE (TTM)Return on equity | -73.9% | +2.4% |
| ROA (TTM)Return on assets | -51.6% | +2.2% |
| ROICReturn on invested capital | -69.9% | +2.6% |
| ROCEReturn on capital employed | -69.2% | +2.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.72x | 0.21x |
| Net DebtTotal debt minus cash | $4M | $999M |
| Cash & Equiv.Liquid assets | $20M | $532M |
| Total DebtShort + long-term debt | $24M | $1.5B |
| Interest CoverageEBIT ÷ Interest expense | -107.47x | -2.49x |
BIO leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BIO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BIO five years ago would be worth $4,232 today (with dividends reinvested), compared to $1,196 for RPID. Over the past 12 months, BIO leads with a +10.7% total return vs RPID's +10.3%. The 3-year compound annual growth rate (CAGR) favors RPID at 45.6% vs BIO's -12.1% — a key indicator of consistent wealth creation.
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| YTD ReturnYear-to-date | -18.5% | -15.7% |
| 1-Year ReturnPast 12 months | +10.3% | +10.7% |
| 3-Year ReturnCumulative with dividends | +208.4% | -32.0% |
| 5-Year ReturnCumulative with dividends | -88.0% | -57.7% |
| 10-Year ReturnCumulative with dividends | -88.0% | +81.4% |
| CAGR (3Y)Annualised 3-year return | +45.6% | -12.1% |
BIO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
BIO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BIO is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than RPID's 1.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BIO currently trades 75.0% from its 52-week high vs RPID's 51.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.96x | 0.92x |
| 52-Week HighHighest price in past year | $4.94 | $343.12 |
| 52-Week LowLowest price in past year | $2.01 | $211.43 |
| % of 52W HighCurrent price vs 52-week peak | +51.8% | +75.0% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 37.0 |
| Avg Volume (50D)Average daily shares traded | 205K | 306K |
BIO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RPID as "Buy" and BIO as "Buy". Consensus price targets imply 212.5% upside for RPID (target: $8) vs 21.4% for BIO (target: $313).
| Metric | RPIDRapid Micro Biosy… | BIOBio-Rad Laborator… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $312.50 |
| # AnalystsCovering analysts | 4 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +4.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
BIO leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallBio-Rad Laboratories, Inc. (BIO)Leads 5 of 6 categories
Loading custom metrics...
RPID vs BIO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is RPID or BIO a better buy right now?
For growth investors, Rapid Micro Biosystems, Inc.
(RPID) is the stronger pick with 19. 7% revenue growth year-over-year, versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Rapid Micro Biosystems, Inc. (RPID) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RPID or BIO?
Over the past 5 years, Bio-Rad Laboratories, Inc.
(BIO) delivered a total return of -57. 7%, compared to -88. 0% for Rapid Micro Biosystems, Inc. (RPID). Over 10 years, the gap is even starker: BIO returned +81. 4% versus RPID's -88. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RPID or BIO?
By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.
(BIO) is the lower-risk stock at 0. 92β versus Rapid Micro Biosystems, Inc. 's 1. 96β — meaning RPID is approximately 112% more volatile than BIO relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 72% for Rapid Micro Biosystems, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RPID or BIO?
By revenue growth (latest reported year), Rapid Micro Biosystems, Inc.
(RPID) is pulling ahead at 19. 7% versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to 2. 8% for Rapid Micro Biosystems, Inc.. Over a 3-year CAGR, RPID leads at 25. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RPID or BIO?
Bio-Rad Laboratories, Inc.
(BIO) is the more profitable company, earning 29. 4% net margin versus -140. 3% for Rapid Micro Biosystems, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIO leads at 10. 5% versus -141. 1% for RPID. At the gross margin level — before operating expenses — BIO leads at 52. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is RPID or BIO more undervalued right now?
Analyst consensus price targets imply the most upside for RPID: 212.
5% to $8. 00.
07Which pays a better dividend — RPID or BIO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is RPID or BIO better for a retirement portfolio?
For long-horizon retirement investors, Bio-Rad Laboratories, Inc.
(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Rapid Micro Biosystems, Inc. (RPID) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +81. 4%, RPID: -88. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between RPID and BIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RPID is a small-cap high-growth stock; BIO is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(RPID: 3.1% · BIO: 1.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.